Antifungal therapy – Page 19

Deep cutaneous phaeohyphomycosis caused by Cladophialophora boppii: A case report

mycolabadmin

A 69-year-old woman with breast cancer developed a skin infection caused by a rare fungus called Cladophialophora boppii while taking dexamethasone for cancer treatment. Doctors diagnosed the infection through skin biopsy and fungal testing, then removed the infected area surgically. After three weeks of antifungal medication (itraconazole), the infection cleared completely and did not return during four months of follow-up. This case suggests that surgery combined with short-term antifungal treatment may be sufficient for this type of infection.

Acute Respiratory Distress Syndrome Due to COVID-19-Associated Pulmonary Aspergillosis with Rare Extensive Tracheobronchial Pseudomembranous Involvement: A Case Report

mycolabadmin

An elderly COVID-19 patient developed a rare and severe fungal infection caused by Aspergillus fungus in the airways, creating yellowish-white membrane-like deposits that blocked breathing. Despite identification of the fungus through examination and modern genetic testing, and treatment with antifungal medications, the patient’s condition worsened rapidly leading to organ failure and death. This case highlights how fungal infections can complicate COVID-19, especially in elderly patients on multiple medications, and stresses the importance of early recognition and immediate antifungal treatment.

Fluconazole worsened lung inflammation, partly through lung microbiome dysbiosis in mice with ovalbumin-induced asthma

mycolabadmin

Fluconazole is an antifungal medication that works well for treating asthma caused by fungal infections, but may actually worsen asthma from other causes. In mice with allergic asthma, fluconazole killed beneficial bacteria and promoted the growth of harmful bacteria that increased inflammation. This study suggests that fluconazole should only be used for fungal-related asthma and careful monitoring is needed if used in patients with regular asthma.

Rhinocerebral Mucormycosis in a Patient With Diabetes: A Rare but Critical Infection in the United Arab Emirates

mycolabadmin

A middle-aged man with undiagnosed diabetes developed a serious fungal infection called mucormycosis that affected his sinuses, eyes, and brain. He presented with flu-like symptoms and facial weakness, and blood tests showed dangerously high blood sugar and acid levels (diabetic ketoacidosis). Doctors treated him with multiple rounds of antifungal medications, several surgeries, and innovative injections directly into and around his eyes and spinal cord, resulting in his successful recovery and discharge.

Clinical insights into mixed Candida and bacterial bloodstream infections: a retrospective cohort study

mycolabadmin

This study found that when both Candida fungus and bacteria are present together in a patient’s bloodstream, the outcome is much more serious than when only Candida is present. Among patients with these mixed infections, over 60% died within 30 days compared to about 52% for those with only Candida. The research shows that giving the right antibiotics early and following proper treatment guidelines can significantly improve survival chances in these severe, life-threatening infections.

Cryptococcus albidus (Naganishia albida) meningitis in a young patient with T-cell acute lymphoblastic leukaemia

mycolabadmin

A 16-year-old boy with blood cancer (T-ALL) developed a brain infection caused by a rare fungus called Cryptococcus albidus. Doctors initially thought he had a viral infection caused by herpes, but tests on his spinal fluid revealed the true fungal culprit. He was treated with antifungal medications that led to his recovery, emphasizing the importance of thorough testing when immunocompromised patients develop serious infections.

Efficacy and safety of isavuconazole for invasive fungal infections: A systematic review and meta-analysis of randomized controlled trials

mycolabadmin

Isavuconazole is an antifungal medication used to treat serious fungal infections in people with weakened immune systems. This study reviewed and analyzed three clinical trials to compare how well isavuconazole works compared to other antifungal drugs. The results showed that isavuconazole is just as effective as other antifungals but has fewer side effects, particularly fewer problems with liver health and drug-related adverse events. This makes isavuconazole a good alternative choice for patients who cannot use other antifungal medications or who are at risk of liver damage.

Graphene nanomaterials: A new frontier in preventing respiratory fungal infections

mycolabadmin

Scientists are exploring nano-graphene oxide, a microscopic material made from graphene, as a new treatment for serious lung fungal infections. These tiny particles can kill fungal cells through multiple mechanisms and deliver antifungal drugs directly to infection sites while reducing harmful side effects. Researchers found that graphene oxide can be combined with existing antifungal medications to make them work better and even help overcome drug-resistant fungal infections.

Breaking the mould: challenging the status quo of clinical trial response definitions for invasive fungal diseases—a debate

mycolabadmin

Doctors and researchers use standard definitions to determine if antifungal treatments work in clinical trials. This debate examines whether the standards created in 2008 are still appropriate today. Key concerns include whether stable disease should always count as treatment failure, how to handle deaths from other causes, and whether newer testing methods should be incorporated. The expert panel concluded these definitions need updating to reflect modern treatment options and patient needs.

Clinical characterization of immunocompetent patients with Scedosporium detected in respiratory samples: A case series

mycolabadmin

This study examined eight elderly patients without compromised immune systems who had Scedosporium fungus detected in their lungs. All patients had a condition called bronchiectasis and most had previously suffered from a lung infection called MAC disease. The researchers found that in most cases, the fungus was simply living in the lungs without causing active infection, though distinguishing between these two situations proved difficult. Only one patient was diagnosed with an active Scedosporium infection and required antifungal treatment with a drug called voriconazole.

Research Topic: Antifungal therapy